Last reviewed · How we verify

NCT05572138: BIAMI

Body Impedance Analysis to Detect ICUAW

Completed Last updated 6 February 2024
What this trial tests

trial testing Body Impedance Analysis in Critical Illness in 62 participants. Completed in 28 January 2024.

Timeline
8 February 2023
Primary endpoint
28 January 2024
28 January 2024

Quick facts

Lead sponsorCharite University, Berlin, Germany
StatusCompleted
Study typeOBSERVATIONAL
Enrollment62
Start date8 February 2023
Primary completion28 January 2024
Estimated completion28 January 2024
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated. The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05572138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing